熊去氧胆酸治疗肝内胆汁淤积症临床观察研究

Clinical study of ursodeoxycholic acid on patients of cholestasis hepatic diseases

目的对比观察应用熊去氧胆酸(UDCA)治疗肝内胆汁淤积症的疗效及安全性。方法连续收集该院199例肝内胆汁淤积患者,分为UDCA治疗组与常规保肝药对照组,比较二组治疗前后症状体征和肝生化指标的改善程度。结果UDCA组显效63例,有效48例,无效26例,总有效率为81.02%;对照组显效18例,有效24例,无效20例,总有效率为67.74%。熊去氧胆酸能显著改善患者的肝功能生化指标,其中总胆红素、结合胆红素、r-谷氨酰转移酶下降幅度高于对照组(P<0.05)。治疗观察期间,两组均未见严重不良反应。结论熊去氧胆酸在对肝内胆汁淤积性肝病患者住院治疗期间疗效较满意,安全性良好。

Aim To evaluate the efficacy and safety of ursodeoxycholic acid in the treatment of cholestasis hepatic diseases with comparison study.Methods One hundred and ninty-nine patients with cholestasis hepatic diseases were divided into the UDCA treatment group and the common hepatoprotective control group.Improvement of symptom signs and hepatic biochemical indicator were compared before and after the treatment.Results There were sixty-three excellent,forty-eight effective,and twenty-six ineffective in UDCA group,with a total effective rate of 81.02%.There were eighteen excellent,twenty-four effective,and twenty ineffective in control group,with a total effective rate of 67.74%.UDCA could significantly improve liver biochemistry.The decreases on total bilirubin,conjugated bilirubin and r-glutamyltransferase in the treatment group were much higher than those in the control group（P〈0.05）,but had no effect on pruritus and so on.The side effect of two groups was mild in the whole process of treatment.Conclusion Combined therapy with UDCA is effective in improving patients with cholestasis hepatic diseases,and UDCA has no evident side effect in such patients.